COVID-19 vaccine developed by China's CanSino to continue advancing phase-3 trials: report
BEIJING - China's CanSino Biologics Inc has got green light to continue phase-3 trials of its COVID-19 vaccine with the support of findings of an independent data monitoring committee, said recent media reports.
The independent committee "found the drugmaker's COVID-19 vaccine met its pre-specified primary safety and efficacy targets under an interim analysis of phase-3 trial data," Reuters cited the biopharmaceutical company to report on Monday.
"No adverse events related to the vaccine had occurred," the report said.
The vaccine candidate, referred to as Ad5-nCoV, is developed by CanSino Biologics Inc and the Academy of Military Sciences in China.
CanSino was approved to conduct phase-3 clinical trials in some countries in Europe and Asia, Wu Yuanbin, an official with China's Ministry of Science and Technology, said in September last year.
- Shijiazhuang's China-Europe freight trains surpass last year's total by October
- China's electricity consumption maintains steady growth in September
- Vapor swirls over water in spectacular weather phenomenon at Tianchi Lake
- Chinese institutes launch powerful AI model to find disease-causing gene mutations
- CPC Central Committee to hold news conference on plenary session
- Conference calls for tech innovations to fight weed menace
